1.
Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, Na KS, Schaumberg
D, Uchino M, Vehof J et al: TFOS DEWS II Epidemiology Report. The ocular surface 2017, 15(3):334-365.
2.
Farrand KF, Fridman M, Stillman IO, Schaumberg DA: Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18
Years and Older. American journal of ophthalmology 2017, 182:90-98.
3.
Vehof J, Kozareva D, Hysi PG, Hammond CJ: Prevalence and risk factors of dry eye disease in a British female cohort. The British journal of ophthalmology 2014, 98(12):1712-1717.
4.
Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, Liu Z, Nelson JD, Nichols
JJ, Tsubota K et al: TFOS DEWS II Definition and Classification Report. The ocular surface 2017, 15(3):276-283.
5.
Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, Knop E, Markoulli
M, Ogawa Y, Perez V et al: TFOS DEWS II pathophysiology report. The ocular surface 2017, 15(3):438-510.
6.
Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, Gupta PK, Karpecki
P, Lazreg S, Pult H et al: TFOS DEWS II Diagnostic Methodology report. The ocular surface 2017, 15(3):539-574.
7.
Baiza-Duran L, Medrano-Palafox J, Hernandez-Quintela E, Lozano-Alcazar J, Alaniz-de
la OJ: A comparative clinical trial of the efficacy of two different aqueous solutions of
cyclosporine for the treatment of moderate-to-severe dry eye syndrome. The British journal of ophthalmology 2010, 94(10):1312-1315.
8.
Chen M, Gong L, Sun X, Xie H, Zhang Y, Zou L, Qu J, Li Y, He J: A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients
with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind,
parallel-group trial. Journal of ocular pharmacology and therapeutics : the official journal of the Association
for Ocular Pharmacology and Therapeutics 2010, 26(4):361-366.
9.
Takamura E, Tsubota K, Watanabe H, Ohashi Y: A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate
ophthalmic solutions in dry eye patients. The British journal of ophthalmology 2012, 96(10):1310-1315.
10.
Matsumoto Y, Ohashi Y, Watanabe H, Tsubota K: Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome:
a Japanese phase 2 clinical trial. Ophthalmology 2012, 119(10):1954-1960.
11.
Park DH, Chung JK, Seo DR, Lee SJ: Clinical Effects and Safety of 3% Diquafosol Ophthalmic Solution for Patients With
Dry Eye After Cataract Surgery: A Randomized Controlled Trial. American journal of ophthalmology 2016, 163:122-131.e122.
12.
Arita R, Suehiro J, Haraguchi T, Maeda S, Maeda K, Tokoro H, Amano S: Topical diquafosol for patients with obstructive meibomian gland dysfunction. The British journal of ophthalmology 2013, 97(6):725-729.
13.
Yokoi N, Kato H, Kinoshita S: The increase of aqueous tear volume by diquafosol sodium in dry-eye patients with
Sjogren's syndrome: a pilot study. Eye (London, England) 2016, 30(6):857-864.
14.
Lee JH, Song IS, Kim KL, Yoon SY: Effectiveness and Optical Quality of Topical 3.0% Diquafosol versus 0.05% Cyclosporine
A in Dry Eye Patients following Cataract Surgery. Journal of ophthalmology 2016, 2016:8150757.
15.
Yang JM, Choi W, Kim N, Yoon KC: Comparison of Topical Cyclosporine and Diquafosol Treatment in Dry Eye. Optometry and vision science : official publication of the American Academy of Optometry
2015, 92(9):e296-302.
16.
Lemp MA: Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. The CLAO journal : official publication of the Contact Lens Association of Ophthalmologists,
Inc 1995, 21(4):221-232.
17.
Yokoi N, Georgiev GA, Kato H, Komuro A, Sonomura Y, Sotozono C, Tsubota K, Kinoshita
S: Classification of Fluorescein Breakup Patterns: A Novel Method of Differential Diagnosis
for Dry Eye. American journal of ophthalmology 2017, 180:72-85.
18.
Pflugfelder SC, de Paiva CS: The Pathophysiology of Dry Eye Disease: What We Know and Future Directions for Research. Ophthalmology 2017, 124(11s):S4-s13.
19.
Savini G, Prabhawasat P, Kojima T, Grueterich M, Espana E, Goto E: The challenge of dry eye diagnosis. Clinical ophthalmology (Auckland, NZ) 2008, 2(1):31-55.
20.
Stevenson W, Chauhan SK, Dana R: Dry eye disease: an immune-mediated ocular surface disorder. Archives of ophthalmology (Chicago, Ill : 1960) 2012, 130(1):90-100.
21.
Lee HK, Ryu IH, Seo KY, Hong S, Kim HC, Kim EK: Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis
sicca patients. Ophthalmology 2006, 113(2):198-205.
22.
Lin T, Gong L: Topical fluorometholone treatment for ocular dryness in patients with Sjogren syndrome:
a randomized clinical trial in China. Medicine 2015, 94(7):e551.
23.
Kim HY, Lee JE, Oh HN, Song JW, Han SY, Lee JS: Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate
in the dry eyes with meibomian gland dysfunction. International journal of ophthalmology 2018, 11(4):593-600.
24.
Hwang HS, Sung YM, Lee WS, Kim EC: Additive Effect of preservative-free sodium hyaluronate 0.1% in treatment of dry eye
syndrome with diquafosol 3% eye drops. Cornea 2014, 33(9):935-941.
25.
Czogalla A: Oral cyclosporine A--the current picture of its liposomal and other delivery systems. Cellular & molecular biology letters 2009, 14(1):139-152.
26.
Lallemand F, Felt-Baeyens O, Besseghir K, Behar-Cohen F, Gurny R: Cyclosporine A delivery to the eye: a pharmaceutical challenge. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft
fur Pharmazeutische Verfahrenstechnik eV 2003, 56(3):307-318.
27.
Ran Y, Zhao L, Xu Q, Yalkowsky SH: Solubilization of cyclosporin A. AAPS PharmSciTech 2001, 2(1):E2.
28.
Gruner P, Riechers B, Chacòn Orellana LA, Brosseau Q, Maes F, Beneyton T, Pekin D,
Baret J-C: Stabilisers for water-in-fluorinated-oil dispersions: Key properties for microfluidic
applications. Curr Opin Colloid Interface Sci 2015, 20(3):183-191.
29.
Ajay T, M.K. Walia, S.L. Hari K: Nanoemulsion in enhancement of bioavailability of poorly soluble drugs: A REVIEW. Pharmacophore 2013, 4:15-25.
30.
Cerpnjak K, Zvonar A, Gasperlin M, Vrecer F: Lipid-based systems as a promising approach for enhancing the bioavailability of poorly
water-soluble drugs. Acta pharmaceutica (Zagreb, Croatia) 2013, 63(4):427-445.
31.
Perry HD, Solomon R, Donnenfeld ED, Perry AR, Wittpenn JR, Greenman HE, Savage HE:
Evaluation of topical cyclosporine for the treatment of dry eye disease. Archives of ophthalmology (Chicago, Ill : 1960) 2008, 126(8):1046-1050.
32.
Salib GM, McDonald MB, Smolek M: Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears
in dry-eye patients having laser in situ keratomileusis. Journal of cataract and refractive surgery 2006, 32(5):772-778.
33.
Jones L, Downie LE, Korb D, Benitez-Del-Castillo JM, Dana R, Deng SX, Dong PN, Geerling
G, Hida RY, Liu Y et al: TFOS DEWS II Management and Therapy Report. The ocular surface 2017, 15(3):575-628.